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Available online 10 April 2016Purpose: ‘Phenocopy’ frontotemporal dementia (phFTD) patients may clinically mimic the behavioral variant of
FTD (bvFTD), but do not show functional decline or abnormalities upon visual inspection of routine neuroimag-
ing. We aimed to identify abnormalities in gray matter (GM) volume and perfusion in phFTD and to assess
whether phFTD belongs to the FTD spectrum. We compared phFTD patients with both healthy controls and
bvFTD patients.
Materials&methods: SevenphFTDand 11 bvFTDpatients, and 20 age-matched controls underwent structural T1-
weighted magnetic resonance imaging (MRI) and 3D pseudo-continuous arterial spin labeling (pCASL) at 3T.
Normalized GM (nGM) volumes and perfusion, corrected for partial volume effects, were quantiﬁed regionally
as well as in the entire supratentorial cortex, and compared between groups taking into account potential con-
founding effects of gender and scanner.
Results: PhFTD patients showed cortical atrophy,most prominently in the right temporal lobe. Apart from this re-
gional atrophy, GM volume was generally not different from either controls or from bvFTD. BvFTD however
showed extensive frontotemporal atrophy. Perfusion was increased in the left prefrontal cortex compared to
bvFTD and to a lesser extent to controls.
Conclusion: PhFTD and bvFTD show overlapping cortical structural abnormalities indicating a continuum of
changes especially in the frontotemporal regions. Togetherwith functional changes suggestive of a compensatory
response to incipient pathology in the left prefrontal regions, these ﬁndings are the ﬁrst to support a possible
neuropathological etiology of phFTD and suggest that phFTD may be a neurodegenerative disease on the FTD
spectrum.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Phenocopy frontotemporal dementia
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Arterial spin labeling-MRI
Cerebral blood ﬂow
Gray matter volume1. Introduction
FTD is a presenile neurodegenerative disorder affecting the frontal and
temporal lobes, with the behavioral variant (bvFTD) as its most common
subtype. BvFTD is characterized by progressive deterioration in social and
personal conduct (Neary et al., 1998). Core clinical features are behavioral
disinhibition, apathy, loss of empathy, and perseverative, stereotypical or
compulsive behavior. In addition to these symptoms, the diagnosis of
probable bvFTD requires frontotemporal changes on neuroimaging and
a gradual decline in functional abilities (Rascovsky et al., 2011). A subset
(reports range from 7% up to 37% (Hornberger et al., 2009; Khan et al.,rasmus MC—University Medical
s.
s).
. This is an open access article under2012)) of predominantlymale patients presents with behavioral changes
characteristic of bvFTD, but without abnormalities on structural magnetic
resonance imaging (MRI) or ﬂuorodeoxyglucose-positron emission to-
mography (FDG-PET) (Davies et al., 2006; Kerklaan et al., 2014; Kipps
et al., 2007; Kipps et al., 2009a). In addition, these patients have a more
benign disease course (Davies et al., 2006) and do not show a decline in
activities of daily living (Mioshi andHodges, 2009). This clinical syndrome
is referred to as ‘phenocopy’ FTD (phFTD) (Hornberger et al., 2008).
Because normal neuroimaging features and no cognitive decline
over time are reported in these patients, a neurodegenerative etiology
is disputed. Autopsy ﬁndings are sparse, but have not shown features
of neurodegeneration (Diehl-Schmid et al., 2007; Kertesz et al., 2005).
Very recently, repeat expansion in the C9ORF72 gene has been associat-
ed with very slowly progressive FTD, resembling phFTD. Some patients
with this mutation have initially been diagnosed with phFTDthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical details of phFTD and bvFTD patients included in the analyses. Described are the behavioral and cognitive proﬁles of phFTD patient at the time of inclusion, and those of bvFTD patients at the time of diagnosis. Also listed are basis of diagnosis,
number of visits and follow up, and (decline) of functional status as assessed by asking patients and/or their caregivers about the patient's ability to perform (instrumental) activities of daily living (as detailed in the Methods).
Behavioral and cognitive proﬁle Diagnosis based on Follow up Functional status
phFTD patients
1 Behavioral symptoms:
Behavioral disinhibition, loss of empathy
No progression for 4 years Clinical
5 visits
5 year FU
Neuropsychological
4 visits
4 year FU
Stable as reported by both patient and caregiver.
Neuropsychological evaluation per domain (3rd visit):
Orientation to person, time, place: unimpaired
Memory: average
Language: below average to average
Attention: average to poor
Executive functions: average to poor
Information processing speed: below average
Visuoconstructive ability: unimpaired
Social cognition: poor
Conclusion: although the impairments listed above are suspect for FTD, the absence of
evident cognitive decline and the long disease course render this diagnosis less likely.
2 Behavioral symptoms:
Behavioral disinhibition, apathy, compulsive behavior, hyperorality
No progression for 9 years Clinical
9 visits
9 years
Neuropsychological
3 visits
8.8 years
Stable as reported by both patient and caregiver.
Neuropsychological evaluation per domain (3rd visit):
Orientation to person, time, place: unimpaired
Memory: unimpaired
Language: average to poor
Attention: average to poor
Executive functions: average to below average
Information processing speed: below average
Visuoconstructive ability: unimpaired
Social cognition: poor
Conclusion: although the impairments listed above and the clinical presentation are
suspect for FTD, the patient's intact insight into his/her own functioning, the absence of
any evident cognitive decline and the very long disease course render this diagnosis less
likely.
3 Behavioral symptoms:
Behavioral disinhibition, loss of empathy, loss of insight
No progression for 1 year Clinical
3 visits
1 year
Neuropsychological
2 visits
1 year
Stable as reported by both patient and caregiver.
Neuropsychological evaluation per domain (2nd visit):
Orientation to person, time, place: unimpaired
Memory: highly variable (unimpaired to poor)
Language: average to poor
Attention: below average to poor
Executive functions: average to poor
Information processing speed: average
Visuoconstructive ability: unimpaired
Social cognition: poor
Conclusion: compared to the previous neuropsychological evaluation there is no
evident cognitive decline.
4 Behavioral symptoms:
Behavioral disinhibition, loss of insight
No progression for 5 years Clinical
5 visits
5 year
Neuropsychological
3 visits
4.8 years
Patient reports minor difﬁculties at work, but
performs activities of daily living independently
and has no difﬁculties operating appliances
according to caregiver.
Neuropsychological evaluation per domain (3rd visit):
Orientation to person and place: unimpaired; to time: sufﬁcient
Memory: unimpaired to below average
Language: below to above average
Attention: average to poor
Executive functions: below average to poor
Information processing speed: average to below average
Visuoconstructive ability: unimpaired
Social cognition: average
Conclusion: although the impairments listed above and the clinical presentation as
well as the cognitive decline reported by patient and caregiver are suspect for FTD, the
absence of evident cognitive decline renders this diagnosis less likely.
5 Behavioral symptoms:
Behavioral disinhibition, apathy, loss of empathy
No progression for 6 years Clinical
9 visits
6 years
Minor difﬁculties reported by patient at ﬁrst and
second visits which had stabilized or improved at
later visits, e.g. disorientation while driving, but notNeuropsychological evaluation per domain (5th visit):
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Neuropsychological
5 visits
5.9 years
anymore when driving using GPS navigation,
conﬁrmed by caregiver.
Orientation to person, time, place: unimpaired
Memory: average
Language: average
Attention: average to above average
Executive functions: above average
Information processing speed: above average
Visuoconstructive ability: unimpaired
Social cognition: below average
Conclusion: the results are similar to previous neuropsychological examinations.
There are no indications for cognitive impairment.
6 Behavioral symptoms:
Behavioral disinhibition, apathy, loss of empathy
No progression for 1.2 years (slight
functional decline but no clinical or
cognitive deterioration).
Clinical
5 visits
1.2 years
Neuropsychological
2 visits
1.2 years
Very slow progression but performs activities of
daily living independently according to caregiver.
Neuropsychological evaluation per domain (2nd visit):
Orientation to person, time, place: unimpaired
Memory: average to poor
Language: average
Attention: below to above average
Executive functions: average to poor
Information processing speed: average
Visuoconstructive ability: unimpaired
Social cognition: below average
Conclusion: although the impairments listed above and the clinical presentation are
suspect for FTD, the patient's intact insight into his/her own functioning and the absence
of any cognitive decline render this diagnosis less likely.
7 Behavioral symptoms:
Behavioral disinhibition, apathy, loss of empathy, hyperorality
No progression for 10 years Clinical
9 visits
10.1 years
Neuropsychological
4 visits
9.7 years
Activities of daily living are scarcely performed due
to the patient's severe apathy according to
caregiver.Neuropsychological evaluation per domain (4th visit):
Orientation to person, time, place: unimpaired
Memory: average to poor
Language: average to poor
Attention: below average to poor
Executive functions: average to poor
Information processing speed: average
Visuoconstructive ability: unimpaired
Social cognition: poor
Conclusion: although the impairments listed above and the clinical presentation as
well as the cognitive decline reported by the caregiver are suspect for FTD, the absence
of evident cognitive decline renders this diagnosis less likely.
bvFTD patients
1 Behavioral symptoms:
Behavioral disinhibition, loss of empathy
Clinical presentation as well as
functional and cognitive decline
Clinical
2 visits
1 year
Neuropsychological evaluation
2 visits
1 years
Functional decline reported by caregiver of several
(instrumental) activities of daily living.
Neuropsychological evaluation per domain (2nd visit):
Orientation to person and place: unimpaired; to time: impaired
Memory: average to poor
Language: below average
Attention: poor
Executive functions: average to poor
Information processing speed: average
Visuoconstructive ability: poor
Conclusion: although previous neuropsychological evaluation did not provide any
indication for a neurodegenerative disorder, the newly reported information by patient
and caregiver and the cognitive decline substantiated by the current evaluation support
the diagnosis of FTD.
2 Behavioral symptoms:
Apathy, loss of empathy
Clinical presentation as well as
functional and cognitive decline
Clinical
3 visits
1.8 years
Neuropsychological evaluation
2 visits
Functional decline reported by patient and
caregiver of several (instrumental) activities of
daily living.Neuropsychological evaluation per domain (2nd visit):
Orientation to person, time, place: unimpaired
Memory: above average to average
Language: unimpaired to below average
(continued on next page)
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Table 1 (continued)
Behavioral and cognitive proﬁle Diagnosis based on Follow up Functional status
1.3 yearsAttention: average to poor
Executive functions: average to below average
Information processing speed: below average
Visuoconstructive ability: below average
Conclusion: compared to the previous neuropsychological evaluation, memory
remained intact, but there is cognitive decline speciﬁcally in the domains of attention
and executive functioning, indicative of a dementia syndrome, most likely FTD.
3 Behavioral symptoms:
Behavioral disinhibition, apathy, loss of empathy, loss of insight, hyperorality
Clinical presentation, functional
decline and cognitive impairment
Clinical
3 visits
2 months
Neuropsychological evaluation
1 visit
Functional decline reported by caregiver of several
(instrumental) activities of daily living.
Neuropsychological evaluation per domain (1st visit):
Orientation to person and time: unimpaired; to place: impaired
Memory: below average to poor
Language: poor
Attention: average to poor
Executive functions: poor
Visuoconstructive ability: average
Conclusion: the cognitive proﬁle is indicative of dementia, clinically presenting as FTD.
4 Behavioral symptoms:
Apathy, loss of empathy, compulsive behavior
Clinical presentation as well as and
functional and cognitive decline
Clinical
3 visits
1.3 years
Neuropsychological evaluation
2 visits
1.3 years
Progressive functional decline as reported by
caregiver.
Neuropsychological evaluation per domain (2nd visit):
Orientation to person, time, place: unimpaired
Memory: poor
Language: below average to poor
Attention: average to poor
Executive functions: unimpaired
Visuoconstructive ability: unimpaired
Information processing speed: below average
Conclusion: the decline in the cognitive domains of langue, attention and information
processing speed compared to the previous neuropsychological evaluation, as well as
the current overall cognitive proﬁle and clinical presentation are indicative of FTD.
5 Behavioral symptoms:
Apathy, loss of insight, stereotyped and compulsive behavior, hyperorality
Clinical presentation as well as
functional and cognitive decline
Clinical
4 visits
2 years
Neuropsychological evaluation
2 visits
1.3 years
Progressive functional decline as reported by
caregiver, eventual admission to nursing home.
Neuropsychological evaluation per domain (2nd visit):
Orientation to person,: unimpaired; to time and place: impaired
Memory: average to poor
Language: average to poor
Attention: below average to poor
Executive functions: poor
Information processing speed: average
Visuoconstructive ability: poor (due to executive dysfunction)
Conclusion: the cognitive decline in domains of attention and executive functioning
and impairment on other domains, combined with the clinical presentation ﬁt the
proﬁle of bvFTD.
6 Behavioral symptoms:
Behavioral disinhibition, compulsive behavior, hyperorality
Clinical presentation as well as
functional and cognitive
impairment.
Clinical
6 visits
2.4 years
Neuropsychological evaluation
1 visit
Minor difﬁculties with operating appliances,
grocery shopping, and laundry, as reported by
caregiver.Neuropsychological evaluation per domain (1st visit):
Orientation to person, time, place: unimpaired
Memory: unimpaired
Language: below average to poor
Attention: below average
Executive functions: below average
Visuoconstructive ability: unimpaired
Conclusion: the mildly impaired attention and executive functions, combined with
impaired language and intact memory and praxis, may be indicative of FTD
7 Behavioral symptoms:
Behavioral disinhibition, loss of empathy, compulsive behavior
Clinical presentation, functional
decline and cognitive impairment.
C9ORF72 mutation present.
Clinical
5 visits
1.5 years
Progressive functional decline as reported by
caregiver, eventual admission to day care (5 days a
week).Neuropsychological evaluation per domain (1st visit):
Orientation to person, time, place: unimpaired
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Neuropsychological evaluation
1 visit
Memory: poor
Language: below average to poor
Attention: average to poor
Executive functions: average
Visuoconstructive ability: average
Conclusion: the focal impairment in the language domain could possibly be attributed
to logopenic progressive aphasia (LPA) but the absence of memory impairment and the
prominent behavioral symptoms are not typical for LPA.
8 Behavioral symptoms:
Behavioral disinhibition, loss of empathy, loss of insight, stereotyped and compulsive
behavior
Screened for MAPT mutation before
the onset of symptoms because of
positive family history. Clinical
conversion to FTD conﬁrmed 1.3
years later (based on clinical
presentation, cognitive and
functional decline).
Clinical
5 visits
1.3 year
Neuropsychological evaluation
2 visits
1.4 year
Functional decline reported initially by patient and
later by caregiver of several (instrumental)
activities of daily living.
Neuropsychological evaluation per domain (2nd visit):
Orientation to person, time, place: unimpaired
Memory: average to below average
Language: below average to poor
Attention: unimpaired
Executive functions: unimpaired to below average
Information processing speed: unimpaired
Visuoconstructive ability: unimpaired
Social cognition: poor
Conclusion: the cognitive proﬁle of impairment in language, memory and social
cognition, combined with the cognitive decline compared to the previous
neuropsychological evaluation and clinical presentation, are compatible with
(conversion to) bvFTD.
9 Behavioral symptoms:
Behavioral disinhibition, apathy, loss of empathy, compulsive behavior
Clinical presentation as well as
functional and cognitive decline.
Clinical
2 visits
1 week
Neuropsychological
1 visit.
Test results of neuropsychological evaluation conducted 6
months earlier elsewhere were also available.
Functional decline of several (instrumental)
activities of daily living decline reported by
caregiver.Neuropsychological evaluation per domain (1st visit, compared to neuropsychological
exam performed elsewhere):
Orientation to person and place: unimpaired; to time: sufﬁcient
Memory: highly variable (unimpaired to poor) average
Language: highly variable (unimpaired to poor)
Attention: unimpaired
Executive functions: average to poor
Information processing speed: below average
Visuoconstructive ability: unimpaired
Social cognition: poor
Conclusion: the cognitive proﬁle of impairment in language, memory and social
cognition, combined with the cognitive decline compared to the previous
neuropsychological evaluation [conducted elsewhere] and clinical presentation, are
compatible with bvFTD.
10 Behavioral symptoms:
Loss of empathy, loss of insight
Clinical presentation, cognitive
impairment and functional decline.
Clinical
4 visits
0.8 year
Neuropsychological
Test results of neuropsychological evaluation conducted
earlier elsewhere were available.
Performs activities of daily living independently
but has progressive difﬁculties operating
appliances and managing ﬁnances, as reported by
caregiver.
Neuropsychological exam conducted elsewhere showed poor performance on multiple
domains, particularly executive functioning and language
11 Behavioral symptoms:
Apathy, loss of empathy
Screened for MAPT mutation when
symptoms ﬁrst manifested because
of positive family history. Diagnosis
based on mutation, clinical
presentation, cognitive and
functional decline.
Clinical
2 visits
1 month
Neuropsychological
Test results of two neuropsychological evaluations with 1.2
year interval conducted elsewhere were available.
Increasing interference with daily functioning, as
reported by caregiver.
Neuropsychological evaluation per domain (2nd neuropsychological exam performed
elsewhere):
Orientation to person and place: unimpaired; to time: impaired
Memory: poor
Language: highly variable (unimpaired to poor)
Attention: unimpaired
Executive functions: below average to poor
Information processing speed: below average
Visuoconstructive ability: unimpaired
Social cognition: poor
Conclusion: compared to the previous evaluation there is a decline in orientation and
language
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600 R.M.E. Steketee et al. / NeuroImage: Clinical 11 (2016) 595–605(Gomez-Tortosa et al., 2014; Khan et al., 2012), but currently, phFTD is
still deﬁned as a clinical syndrome. An alternative notion is that phFTD
patients might have a pre-existent psychiatric disorder and decompen-
sate during mid-life (Kipps et al., 2010; Manes, 2012; Piguet et al.,
2011).
In the present study we used advanced quantitative MRI tech-
niques and analyses to investigate both structural and functional
abnormalities in phFTD in more detail, as the typical behavioral
changes in phFTD imply neurophysiological changes which may be
detected with these advanced methods (Khan et al., 2012). We
used arterial spin labeling (ASL)-MRI to quantify brain perfusion
with higher spatial resolution than thus far achieved with PET
(Wong et al., 1999). Focal atrophy can be detected by regional quan-
tiﬁcation of gray matter volume on structural imaging. Gray matter
volume and perfusion in phFTD patients were compared with both
healthy controls and bvFTD patients in order to assess whether
phFTD belongs to the FTD spectrum.2. Methods
2.1. Participant selection
PhFTD and bvFTD patients were recruited from the Alzheimer
Center Southwest Netherlands at Erasmus MC, Rotterdam, The
Netherlands, which is a tertiary referral center with special focus on
FTD. Exclusion criteria for both phFTD and bvFTD patients were contra-
indications for MR imaging and lack of hetero-anamnestic information.
In addition, phFTD patients were excluded when there was a diagnosis
of dementia, or when other neurological or psychiatric disorders were
suspected.
Of the ﬁfteen patients that fulﬁlled the criteria for phFTD, i.e. be-
havioral features but no imaging ﬁndings consistent with bvFTD, and
no progression for at least one year after initial diagnostic work-up,
six patients declined to participate; one was excluded due to refusal
of neuropsychological assessment; and one eventually showed pro-
gressive cognitive impairment at neuropsychological follow-up,
resulting in the analysis of seven phFTD patients (Table 1). One pa-
tient showing an asymptomatic cortical infarct in the right parietal
lobe on MRI was retained in the analyses, as no residual clinical
symptoms were reported and the infarct was not in a region of inter-
est for FTD. Image processing results were visually checked and did
not show any effect of the infarct on segmentation or registration
procedures. All phFTD patients were screened for the presence of
the repeat expansion of the C9ORF72 gene. We chose to screen for
this causative mutation only, and not other mutations associated
with psychiatric symptoms in bvFTD, as it has been speciﬁcally asso-
ciated with slowly progressive bvFTD (Gomez-Tortosa et al., 2014;
Khan et al., 2012).
Twelve bvFTD patients with possible bvFTD (Rascovsky et al.,
2011) with an onset before 65 years and a Mini Mental State Exami-
nation (MMSE) score ≥20 were prospectively recruited as part of a
larger ongoing study on advanced MR neuroimaging in the early
stage of presenile dementia. If the diagnosis at the initial visit was
uncertain, patients were followed up on until a deﬁnitive diagnosis
was established based on the criteria by (Rascovsky et al., 2011).
One patient was excluded from analysis due to poor perfusion data
quality as a result of severe motion artifacts, resulting in the analysis
of 11 bvFTD patients (Table 1).
Healthy age-matched controls were recruited through advertise-
ment and from the patients' peers. They were matched for gender
with the phFTD patients. Exclusion criteria were history of neurological
or psychiatric disorders and contraindications for MRI. Of the twenty-
three controls, two were excluded due tomissing data and one because
of below-average scores on neuropsychological assessment, resulting in
the analysis of twenty healthy controls.The study was approved by the medical ethics committee of Eras-
mus MC. All participants gave written informed consent.
2.2. Neuropsychological and psychiatric assessment
All participants underwent extensive neuropsychological examina-
tion as part of routine diagnostic work-up, assessing language and
speech, attention and mental processing speed, executive functions,
memory, and social cognition. PhFTD patients had an additional assess-
ment to verify whether they fulﬁlled the criterion of no cognitive de-
cline for at least one year. Additionally, functional status and possible
decline thereof was determined by asking both phFTD and bvFTD pa-
tients and their caregivers about the patient's ability to perform (instru-
mental) activities of daily living, such as cooking, transportation,
ﬁnancial management, grooming, bathing, dressing, and eating. Func-
tional decline excluded the diagnosis of phFTD.
PhFTD patients were assessed by an experienced psychiatrist to rule
out major psychiatric disorders other than dementia. Clinical assess-
ment by the expert psychiatrist was based on interviews with the pa-
tients and their caregivers, the Brief Psychiatric Rating Scale (BPRS
(Overall and Gorham, 1962); Dutch translation (Dingemans, 1986)),
and the psychiatrist's observations. The assessment served to determine
whether pre-existent psychiatric disorderswere absent, such as person-
ality disorders and autism spectrum disorders, that would serve as an
alternative explanation of the current behavioral symptoms. Speciﬁcal-
ly, late-onset psychotic disorders, manic episodes, and depressive or
anxiety disorders were ruled out as these are more likely to mimic
bvFTD (and thus phFTD).
2.3. Image acquisition
Patients underwent MR imaging on two identical 3T scanners (Dis-
covery MR750 system GE Healthcare, USA) with identical protocols.
Seven healthy controls and all phFTD patients were scanned on one,
and 13 healthy controls and all bvFTD patients on the other scanner.
2.3.1. Structural imaging
For gray matter volumetric assessment and anatomical reference, a
high-resolution three-dimensional (3D) inversion recovery (IR) fast
spoiled gradient-echo (FSPGR) T1-weighted (T1w) scan was acquired
(inversion time (TI) 450 ms, echo time (TE) 3.06 ms, repetition time
(TR) 7.904 s, ﬂip angle 12°, ASSET factor 2, isotropic resolution 1 mm3
in a 240 mm ﬁeld of view (FOV), 176 sagittal slices, total acquisition
time 4 min and 41 s).
2.3.2. Perfusion imaging
Perfusion images were acquired using whole brain 3D pseudo-
continuous ASL (p-CASL), currently the recommended sequence for
clinical use (Alsop et al., 2015). With exception of the post labeling
delay (1525 ms in the current study), perfusion scans were acquired
using the recommended parameters (interleaved fast spin-echo stack-
of-spiral readout of 512 sampling points on 8 spirals, background sup-
pressed, labeling duration 1450 ms, TE 10.5 ms, TR 4632 ms, isotropic
resolution 3.3 mm3 in a 240 mm FOV, 36 axial slices, number of excita-
tions (NEX) 3, total acquisition time 4 min and 29 s). The labeling plane
was positioned 9 cm below the anterior commissure–posterior com-
missure line.
2.4. Image data processing
We processed imaging data according to the methods described in
detail by Bron et al., 2014, as brieﬂy outlined below. In summary, cere-
bral bloodﬂow(CBF) values fromgraymatter (GM) corrected for partial
volume effects were obtained using the following methods.
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Using the uniﬁed tissue segmentation method in SPM8 (Statistical
Parametric Mapping, London, UK), we segmented T1w images into
GM, white matter and cerebrospinal ﬂuid maps. The GM maps were
subsequently used to derive GM volumes and CBF.
2.4.2. ASL post-processing
The ASL data consisted of a difference image and a control image.
Quality of all imageswere visually assessed by checking formotion, sus-
ceptibility and watershed artifacts. GM maps were rigidly registered
with the difference image (Elastix registration software (Klein et al.,
2010)) and registrations were checked visually. Tissue maps were
transformed to ASL image space to perform partial volume (PV) correc-
tion, and PV effects in ASL difference and control images were subse-
quently corrected using local linear regression within a 3D kernel
based on tissue maps (Asllani et al., 2008). We quantiﬁed PV-
corrected ASL images as CBF maps using the single-compartment
model (Alsop et al., 2015). CBF maps were transformed to T1w image
space for further analysis.
2.4.3. ROI labeling
We deﬁned regions of interest (ROIs) for each participant using a
multi-atlas approach. This involved registration of 30 labeled T1w
images, each containing 83 cortical and subcortical ROIs (Gousias
et al., 2008; Hammers et al., 2003), to the participants' T1w images.
The labels of the 30 atlas imageswere fused bymeans ofmajority voting
to obtain a ﬁnal ROI labeling (Heckemann et al., 2006). Rigid, afﬁne, and
non-rigid B-spline transformationmodels were applied successively for
registration to the participants' nonuniformity-corrected T1w images
(Tustison et al., 2010). Both the participants' and the labeled T1w im-
ages were masked for this registration using the Brain Extraction Tool
(Smith, 2002).
2.4.4. ROI analysis
For all ROIs, we derived GM volumes and mean GM CBF values
which were checked for outliers due to previously unnoticed artifacts
or registration errors. The subcortical ROIs, cerebellum, brainstem, ven-
tricles and white matter were excluded from analysis. ROIs that
parcellated gyri inmultiple sections were combined to constitute entire
gyri (supplementary Table 1). GM volumes and mean GM CBF values
were subsequently obtained for the left and right hemisphere separate-
ly. Regional GM volumes were divided by the total intracranial volume
to correct for head size and are referred to as normalized GM (nGM)
volumes.
2.5. Data analysis
Using SPSS Statistics, version 20.0 (New York, USA) we ﬁrst ana-
lyzed differences in gender and scanner across groups with Fisher's
exact test. As these were signiﬁcantly different between groups
(p b 0.05), we then used hierarchical regression to sequentially as-
sess the effects of scanner, gender, and group on nGM and CBF.
Only the nGM and regional CBF ROIs that showed a signiﬁcant effect
of group but did not show signiﬁcant effects of scanner and/or gen-
der were further tested for differences between groups. This was
done using a nonparametric Kruskal-Wallis test with Dunn-
Bonferroni correction for multiple comparisons as nGM, CBF, age
and MMSE were not normally distributed across groups (Shapiro-
Wilk test p b 0.05). The ﬁndings were visually represented in
boxplots of nGM and CBF for each of the brain lobes. Statistical
thresholds were set at p b 0.05. Results were visualized by overlaying
the ROIs as deﬁned by Gousias et al., 2008 and Hammers et al., 2003
that showed group differences on a volume render of a skull-
stripped T1w template in MRIcron NIfTI viewer (Chris Rorden, Ver-
sion 1, April 2010).3. Results
3.1. Participant characteristics
Age was not different between groups (H(2) = 1.129, p N 0.05,
Kruskal-Wallis test) (Table 2). MMSE was signiﬁcantly different be-
tween groups (F(2) = 10.182, p b 0.05, Kruskal-Wallis test): both
phFTD and bvFTD patients had signiﬁcantly lower MMSE scores than
controls.
None of the phFTD patients had a C9ORF72mutation, nor could their
behavioral disturbances be attributed to an underlying psychiatric dis-
order. Neuropsychological assessment was normal in one and sugges-
tive of FTD in six phFTD patients, but did not demonstrate progressive
decline.
Median follow-up to establish deﬁnitive diagnosis of bvFTD was
1.4 years (range 1.7 months–2.4 years).
3.2. Gray matter volumetric changes
There were signiﬁcant differences in nGM volume between groups
mostly in frontal and temporal regions (Fig. 1A, Table 3). PhFTDpatients
had lower supratentorial nGM volume than controls which was most
pronounced in the right posterior temporal lobe, right superior tempo-
ral gyrus and bilateral fusiform gyrus. BvFTD showed extensive bilateral
frontotemporal nGM volume loss compared to controls. Compared to
phFTD, bvFTD showed lower nGMvolume in the right hippocampal for-
mation and the right amygdala. Other nGM volumes were not signiﬁ-
cantly different between bvFTD and phFTD. This spectrum of ﬁndings,
with mean nGM volumes being highest in controls, lowest in bvFTD
and in-between in phFTD, was particularly apparent in the frontal and
temporal lobes (Fig. 2A).
3.3. Perfusion changes in the gray matter
There were signiﬁcant differences in CBF between groups in frontal
regions (Fig. 1B, Table 4). CBF in the bilateral subcallosal areawas higher
in phFTD than both in bvFTD and controls, as illustrated in Fig. 2B. CBF in
bvFTD was lower than in phFTD in the left superior and inferior frontal
gyrus, the left orbitofrontal gyrus, and in the bilateral straight gyrus.
bvFTD showed lower CBF than controls in the left inferior frontal and
straight gyrus, and the left orbitofrontal gyrus. Note that differences be-
tween groups were not located in watershed regions and can therefore
not be attributed to watershed artifacts.
4. Discussion
To the best of our knowledge, our study is the ﬁrst to show cortical
brain abnormalities in phFTD. We found cortical atrophy in phFTD,
most prominently in the right superior and posterior temporal lobe,
and the fusiform gyrus bilaterally. Furthermore, we found left frontal
hyperperfusion in phFTD compared to bvFTD and to a lesser extent to
controls, which may reﬂect functional compensation for incipient
pathology.
Regional right temporal atrophywas not only seen in phFTDbut also
present in bvFTD, suggesting similar underlying pathophysiology. Atro-
phy in right temporal regions has been linked to impaired emotion rec-
ognition and empathy in neurodegenerative disease (Rankin et al.,
2006; Rosen et al., 2006), and more speciﬁcally to emotional blunting
in bvFTD (Lee et al., 2014). In addition, frontotemporal atrophy
lateralized to the right hemisphere is more often associatedwith social-
ly undesirable behavior in FTD than when lateralized to the left
(Mychack et al., 2001). The fact thatwe found atrophy in this speciﬁc re-
gion may explain why symptoms in phFTD patients are mostly isolated
to the behavioral domain, in contrast to bvFTD patients who show a
more widespread frontotemporal atrophy and additional cognitive
and functional decline.
Table 3
Median nGM volume [% ICV] and 25th and 75th percentile (in parentheses) for healthy
controls (HC), phFTD and bvFTD patients.
Region of interest
Healthy controls PhFTD BvFTD
Median
(25th–75th %ile)
Mean
rank
Median
(25th–75th %ile)
Mean
rank
Median
(25th–75th %ile)
Mean
rank
Supratentorial cortex 35.3 (33.3–36.1) 26 31.6 (30.0–33.6) 13a 29.1 (27.2–34.1) 11c
L Superior frontal gyrus 1.62 (1.56–1.68) 26 1.50 (1.41–1.56) 15 1.21 (1.00–1.59) 11c
R Superior frontal gyrus 1.62 (1.48–1.75) 25 1.55 (1.40–1.60) 18 1.17 (1.02–1.51) 11c
L Middle frontalgyrus 1.29 (1.14–1.41) 23 1.20 (1.17–1.35) 20 0.95 (0.82–1.27) 12c
R Middle frontalgyrus 1.27 (1.18–1.35) 25 1.17 (1.13–1.24) 17 0.98 (0.75–1.27) 12c
R Inferiorfrontalgyrus 0.57 (0.54–0.62) 24 0.54 (0.50–0.59) 19 0.44 (0.40–0.52) 11c
L Straight gyrus 0.15 (0.14–0.18) 25 0.15 (0.11–0.17) 20 0.10 (0.09–0.13) 10c
R Straight gyrus 0.17 (0.15–0.19) 26 0.14 (0.12–0.19) 18 0.12 (0.09–0.13) 9c
L Orbitofrontalgyrus 0.79 (0.73–0.84) 25 0.74 (0.60–0.76) 15 0.47 (0.39–0.76) 12c
R Orbitofrontalgyrus 0.80 (0.76–0.85) 25 0.67 (0.64–0.78) 14 0.53 (0.44–0.77) 12c
R Anteriorcingulate gyrus 0.33 (0.29–0.39) 25 0.31 (0.28–0.32) 18 0.26 (0.20–0.29) 11c
L Insula 0.54 (0.51–0.55) 25 0.51 (0.46–0.53) 19 0.39 (0.36–0.49) 9c
R Insula 0.50 (0.49–0.53) 26 0.47 (0.46–0.50) 19 0.37 (0.34–0.42) 8c
L Anteriortemporal lobe 0.44 (0.41–0.49) 25 0.44 (0.38–0.46) 21 0.34 (0.27–0.37) 9c
R Anteriortemporal lobe 0.48 (0.44–0.52) 26 0.45 (0.39–0.49) 19 0.34 (0.26–0.38) 9c
L Posterior temporal lobe 1.70 (1.66–1.74) 24 1.69 (1.50–1.74) 18 1.58 (1.43–1.65) 12c
R Posterior temporal lobe 1.82 (1.75–1.89) 26 1.60 (1.53–1.63) 11a 1.57 (1.44–1.76) 13c
L Hippocampal formation 0.39 (0.35–0.41) 24 0.37 (0.32–0.42) 21 0.29 (0.24–0.34) 10c
R Hippocampal formation 0.38 (0.36–0.40) 24 0.37 (0.32–0.42) 22b 0.28 (0.26–0.37) 9c
L Amygdala 0.09 (0.08–0.09) 24 0.09 (0.07–0.09) 20 0.07 (0.07–0.08) 12c
R Amygdala 0.08 (0.07–0.08) 22 0.08 (0.07–0.09) 26b 0.07 (0.05–0.08) 11c
L Superior temporal gyrus 0.71 (0.70–0.78) 25 0.63 (0.55–0.71) 15 0.59 (0.58–0.66) 12c
R Superior temporal gyrus 0.72 (0.68–0.79) 26 0.65 (0.58–0.70) 13a 0.64 (0.51–0.71) 12c
L Inferiortemporal gyrus 0.70 (0.62–0.74) 26 0.66 (0.54–0.67) 17 0.50 (0.38–0.60) 9c
R Inferiortemporal gyrus 0.72 (0.62–0.76) 26 0.65 (0.54–0.67) 18 0.50 (0.35–0.59) 9c
L Fusiform gyrus 0.22 (0.19–0.22) 26 0.16 (0.15–0.19) 14a 0.17 (0.11–0.18) 11c
R Fusiform gyrus 0.21 (0.19–0.24) 26 0.16 (0.14–0.19) 12a 0.15 (0.13–0.18) 11c
L Remainder of parietallobe 1.33 (1.25–1.42) 25 1.24 (1.17–1.31) 15 1.16 (1.05–1.32) 13
c
Median nGM volumes and 25th and 75th percentile in ROIs for which post hoc pairwise comparisons
showed significant different mean ranks between healthy controls, phFTD and bvFTD patients. The mean
ranks (italics) represent the group means of the rank-ordered nGM data in that particular ROI. The mean
ranks rather than the medians of the nGM volume distributions were compared to assess differences
between groups because group distributions were not similarly shaped. The shading indicates the relative
order of mean ranks between groups, with light gray indicating the highest and dark gray indicating the
lowest rank.
aphFTD < controls; p ≤ .05.
bbvFTD < phFTD; p ≤ .05.
cbvFTD < controls; p ≤ .05.
nGM = normalized gray matter; ICV = intracranial volume; ROIs=regions of interest; PhFTD = phenocopy
frontotemporal dementia; bvFTD = behavioral variant frontotemporal dementia; HC=healthy controls; L=
left; R = right.
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in phFTDwas foundusing semi-quantitative ratings (Davies et al., 2006;
Pennington et al., 2011). One possible explanation might be that such
semiquantitative rating was not sufﬁciently sensitive. However, other
studies using the potentially more sensitive VBM method did not
show any abnormalities either (Kipps et al., 2009a; Kipps et al.,
2009b), except for one case study reporting non-speciﬁc parieto-
occipital, thalamic and subtle frontoinsular atrophy (Khan et al.,
2012). The discrepancy with the present study may lie in the fact that
we used highly speciﬁc patient selection criteria, i.e. behavioral features
consistent with bvFTD, without progression for at least one year, with-
out psychiatric disorders and without C9ORF72 mutations. It may also
be due tomethodological differences between voxel-wise and ROI anal-
yses. ROI analysis circumvents the problem of inter-individual anatom-
ical variability, aswell as subsequent corrections for such variability that
may compromise resolution (such as smoothing). Additionally, statisti-
cal power of ROI analysis is hampered less by corrections for multiple
comparisons than voxel-wise testing.
Apart from the focal right temporal atrophy, nGM volumes in phFTD
were generally not different fromneither bvFTD nor from controls. Only
the right hippocampal formation and amygdala showed more atrophy
in bvFTD compared with phFTD, suggesting preservation of those re-
gions in phFTD, whereas these were severely affected in bvFTD
(Barnes et al., 2006). Of note is that otherwise, nGM volumes were sim-
ilar between phFTD and bvFTD, despite widespread GM loss in bvFTD
compared to controls. These ﬁndings suggest that there is a continuum
in nGM volumes ranging from normal on the one end to clearly abnor-
mal in bvFTD on the other, with phFTD in-between. Together with the
overlapping ﬁnding in both phFTD and bvFTD of right temporal lobe at-
rophy, this suggests that phFTD may be a disease on the FTD spectrum.
Our study was the ﬁrst to use ASL-MRI in phFTD to assess perfusion.
ASL is tightly coupled to brain metabolism and function as measured
with FDG-PET, but previous PET studies failed to ﬁnd any abnormalities
in phFTD (Kerklaan et al., 2014; Kipps et al., 2009a). We found higher
perfusion in phFTD in the bilateral straight gyrus and left superior, infe-
rior and orbital frontal gyrus compared to bvFTD, and to a lesser extent
compared to controls. Some of these regions, i.e. in the left inferior fron-
tal gyrus, correspond to those showing hypoperfusion in bvFTD com-
pared to controls. Such hyperperfusion in phFTD relative to bvFTD
may reﬂect a compensatory process of increased activity to compensate
for incipient pathology in regions affected in bvFTD (Hu et al., 2010).
Such functional compensation is not commonly seen in clinical cases
of bvFTDpatients, particularly not on FDG-PET. As ASL and FDG-PET cor-
relate generally well (Cha et al., 2013; Chen et al., 2011), such occasion-
ally reported hyperperfusion with ASL may in fact be the result of a
commonly applied normalization procedure, in which CBF is divided
by gray matter volume. Because in bvFTD atrophy often exceeds hypo-
perfusion (Zhang et al., 2011), division of relatively intact CBF by rela-
tively extensive volume loss may lead to an overestimation of
(corrected) CBF and thus hyperperfusion. Similarly, hypermetabolism
has been observed after global but not cerebellar normalization of FDG
PET data in frontotemporal dementia (e.g. Dukart et al., 2010). In the
present study, we did not divide CBF by graymatter volume (only by in-
tracranial volume to correct for head size) and therefore did not artiﬁ-
cially ‘induce’ hyperperfusion. Our ﬁndings in bvFTD patients are thusTable 2
Participant characteristics.
Controls phFTD bvFTD
N (male) 20 (20) 7 (7) 11 (5)
Median age in years
(25th–75th percentile)
64 (62–66) 61 (60–70) 63 (57–66)
Median MMSE (25th–75th percentile) 28 (28–30) 27 (26–28) 27 (24–28)
bvFTD= behavioral variant frontotemporal dementia; IQR= interquartile range; MMSE=
Mini Mental State Examination; phFTD = phenocopy frontotemporal dementia; SD =
standard deviation.in line with the extensive FDG-PET literature (e.g. Diehl-Schmid et al.,
2007), and the fact that we did not ﬁnd hyperperfusion in bvFTD, but
only in phFTD patients leads us to speculate that such hyperperfusion
may be unique to phFTD pathophysiology.
A similar pattern of hyperperfusion could be observed in the right
straight gyrus, where perfusion was increased in phFTD compared to
bvFTD, while there was a trend (p = 0.06) towards hypoperfusion in
bvFTD compared to controls. The other hyperperfused regions in
phFTD relative to bvFTD, namely the superior frontal gyrus and
subcallosal region, did not show hypoperfusion in bvFTD. Although
not observed in our bvFTD sample, left superior frontal hypoperfusion
has been found in FTD in previous ASL studies (Du et al., 2006; Tosun
et al., 2012; Zhang et al., 2011). Similarly, PET studies have reported
subcallosal hypometabolism in FTD (Kanda et al., 2008; Salmon et al.,
2003; Schroeter et al., 2007). Therefore, a compensatory process may
still be hypothesized. Possible functional compensation would be ex-
pected to occur prior to volume loss, and in fact the regions that showed
hyperperfusion did not show any clear volume loss, in line with this
Fig. 1. Schematic overview of cortical regions showing (A) normalized GM volume and (B) perfusion abnormalities. Panel 1A shows in red regional nGM atrophy present in both phFTD
and bvFTD; in blue regional nGM volume loss in bvFTD compared to both phFTD and controls; and in yellow regional nGM volume loss in in bvFTD when compared to controls, but not
compared to phFTD. Panel 1B shows in cyan hyperperfusion in phFTD compared to bvFTD in regions that show hypoperfusion in bvFTD compared to controls; in green regional
hyperperfusion in phFTD compared to both bvFTD and controls; and in violet regional hyperperfusion in phFTD compared to bvFTD. HC = healthy controls; phFTD = phenocopy
frontotemporal dementia; bvFTD= behavioral variant frontotemporal dementia; nGM= normalized gray matter.
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exclude an ongoing process of functional compensation with an upreg-
ulation of remaining functional tissue. On the other hand, it can be pos-
tulated that in the context of functional compensation volume loss is
expected to occur at some point, which would not be consistent with
the observations in phFTD to date. However, this is not necessarily the
case if neuronal dysfunctioning is largely non-progressive. Because ofFig. 2. A) normalized GM (% ICV) and B) CBF (ml/100 g GM/min) in the different lobes for heal
from lower to upper quartile (25-75th percentile), the middle line represents the median, and
extreme values (value ≥ 1.5× interquartile range). Note that GMvolumes inphFTD are generally
bvFTD and controls. HC = healthy controls; phFTD = phenocopy frontotemporal dementia;
ICV = intracranial volume; CBF = cerebral blood ﬂow.the cross-sectional design of the study, any interpretation in this context
remains speculative.
Taken together, our ﬁndings in phFTD suggest functional compensa-
tion as well as focal structural abnormalities overlapping with those
found in bvFTD. Overlapping focal cortical atrophy was limited to the
right temporal lobe, consistent with the disease-speciﬁc prominent be-
havioral changes of phFTD, while cortical volumes in the remainingthy controls (HC), phFTD (PH) and bvFTD (BV) patients. The central box represents values
vertical bars extend fromminimum to maximum value. Spheres outside the bars indicate
in-between those of HC and bvFTD, and that perfusion inphFTD is generally higher than in
bvFTD = behavioral variant frontotemporal dementia; nGM= normalized gray matter;
Table 4
Median CBF and 25th and 75th percentile (in parentheses) for healthy controls (HC),
phFTD and bvFTD patients.
Region of interest
Healthy controls PhFTD BvFTD
Median
(25th–75th %ile)
Mean
rank
Median
(25th–75th %ile)
Mean
rank
Median
(25th–75th %ile)
Mean
rank
L
Superior frontal
gyrus
38.1 (34.5–45.4) 19 46.0 (39.0–65.0) 28b 35.0 (29.6–43.8) 15
L Inferior frontal gyrus 48.6 (40.5–51.1) 22 50.7 (43.8–60.7) 27b,c 38.1 (31.1–42.3) 11b
L Straight gyrus 49.8 (44.6–54.3) 22 55.1 (46.4–63.7) 27b,c 38.1 (35.2–46.6) 11b
R Straight gyrus 47.0 (43.6–50.1) 21 51.7 (44.0–62.6) 28b 38.7 (32.5–45.0) 11
L Orbitofrontal gyrus 44.1 (40.3–48.8) 23 43.0 (38.5–62.6) 25b,c 35.9 (30.3–38.7) 10b
L Subcallosal area 31.6 (25.3–42.4) 19 45.0 (40.1–50.8) 32a,b 23.8 (20.4–32.4) 12
R Subcallosal area 27.8 (22.4–41.8) 19 42.8 (41.3–48.2) 31a,b 29.5 (17.9–34.6) 13
Median CBF and 25th and 75th percentile in ROIs for which posthoc pairwise comparisons showed
significant different mean ranks between healthy controls, phFTD and bvFTD patients. The mean ranks
(italics) represent the group means of the rank-ordered CBF data in that particularROI. The mean ranks
rather than the medians of the CBF value distributions were compared to assess differences between
groups because group distributionswere not similarlyshaped. The shading indicates the relative order of
mean ranks between groups, withlightgray indicatingthe highest and dark gray indicatingthe lowest
rank.
aphFTD > controls; p ≤ .05.
bbvFTD < phFTD; p ≤ .05.
cbvFTD < controls; p ≤ .05.
CBF = cerebral blood flow; ROIs = regions of interest; phFTD = phenocopy frontotemporal dementia;
bvFTD = behavioral variant frontotemporal dementia;HC = healthycontrols; L = left; R = right.
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These ﬁndings support the idea that phFTD is a disease of the FTD spec-
trum. One could even wonder whether phFTD is not simply an early
manifestation of bvFTD. The notion of phFTD as a neurodegenerative
disease is however still disputed due to the absence of disease progres-
sion in these patients. Psychiatric disorders have been proposed as an
alternative or contributory etiology (Gossink et al., 2016; Kipps et al.,
2010; Manes, 2012; Piguet et al., 2011). In support of this view, imaging
ﬁndings show substantial overlap between FTD and disorders such as
schizophrenia (Andreasen et al., 1997;Olabi et al., 2011) anddepression
(Dotson et al., 2009; Drevets et al., 1997). In addition, phFTD patients
may carry a C9ORF72 mutation (Gomez-Tortosa et al., 2014; Khan et al.,
2012) which is not only associated with bvFTD, but also with psychotic
symptoms (Snowden et al., 2012). Hence, there is substantial overlap be-
tween phenotype and possibly genotype of psychiatric syndromes and
the FTD spectrum. Yet in our phFTD patients, alternative psychiatric diag-
noses were ruled out, which renders interpretation in the context of neu-
rodegenerative disease more likely. In addition, none of the phFTD
patients had a mutation of the C9ORF72 gene. Therefore, as of yet,
phFTD still seems to be described best as a clinical syndrome. As such,
our phFTD population comprised patients with a distinct clinical proﬁle:
behavioral features consistent with bvFTD, without progression for at
least one year, without psychiatric disorders and without the C9ORF72
mutation. This well-deﬁned clinical proﬁle may have enabled a ﬁrst link
between the typical behavioral changes in phFTD and potential neuro-
physiological changes as detectedwith imaging. In support of this, the im-
aging abnormalities observed in our phFTD sample showed almost full
spatial overlap with those observed in the bvFTD sample. Nevertheless,
future studies deﬁning the spectrum of both neurodegenerative and psy-
chiatric etiologies that cause behavioral changes later in life (Krudop et al.
2014) are necessary to resolve this debate.
The present study has some limitations. Firstly, the sample size was
small. This is inherent to phFTD being a rare disease, with only 15 doc-
umented cases in a large tertiary referral center as ours. Of note is that
the current literature on phFTD has the same limitation, with a median
sample size of only 9 patients. Many studies report ﬁndings based oncases or case series (N = 1–4; Diehl-Schmid et al., 2007;
Gomez-Tortosa et al., 2014; Khan et al., 2012; Kipps et al., 2007). Studies
investigating larger samples (N=8–26; Davies et al., 2006; Hornberger
et al., 2008; Hornberger et al., 2009; Kerklaan et al., 2014; Kipps et al.,
2009a; Kipps et al., 2009b; Mioshi and Hodges, 2009) generally did
not apply such stringent in- and inclusion criteria as we did, i.e. not ad-
hering to all but only some of the criteriawe used such as 1) clinical pre-
sentation with bvFTD symptomatology, 2) cognitive decline as assessed
with repeated comprehensive neuropsychological testing, 3) repeated
self-reported functional status by patient and caregiver, 4) explicit ex-
clusion of other psychiatric disorders as assessed by an experienced psy-
chiatrist, and 5) controlling for the presence of the C9ORF72 mutation
associated with slowly progressive bvFTD. This variation in patient se-
lection indicates the trade-off between sample size and potential pa-
tient heterogeneity in the context of rare disease. We chose to study a
very well-deﬁned phFTD sample, by strictly controlling for disease pro-
gression and alternative psychiatric etiology, at the cost of sample size
and thus statistical power and generalizability. One patient did have
an asymptomatic cortical infarct in the right parietal lobe, but as this
did not affect image processing results we expect it did not inﬂuence
our ﬁndings. Secondly, groups were not fully gender-matched and
were scanned on two-albeit identical-scanners. We used hierarchical
regression analysis to account for potential confounding effects of gen-
der and scanner. Although this stringent analysis limited the number
of regions that were eventually analyzed between groups and carries
the risk of false negative results, it decreased the probability of false pos-
itives, and as such strengthens the validity of our ﬁndings. Finally, de-
spite a one year follow-up to ensure the absence of progression,
longer follow-up in a longitudinal studywill be even better suited to as-
sess whether patients show no or very slow progression. Therefore,
follow-up of our phFTD sample is currently ongoing. In addition, the
ﬁndings in the current study are based on group analysis which may
not necessarily generalize to the individual patient level. In our
follow-up study we intend to describe patients also on an individual
basis, taking longitudinal ﬁndings into account. Ultimately, post-
mortemexamination is essential to determinewhether neuropathology
is present and if so, what type. Hence, studies investigating both neuro-
degenerative etiology and neuropsychiatric presentation of behavioral
changes later in life (Krudop et al., 2014)may further elucidate the rela-
tionship between behavior and neurophysiology.
In conclusion, in addition to overlapping focal right temporal lobe at-
rophy in phFTD and bvFTD,we found a continuumof frontotemporal cor-
tical volumes ranging from normal on the one end to clearly abnormal in
bvFTD on the other, with phFTD in-between. Furthermore, we observed
left frontal hyperperfusion in phFTD, suggestive of a compensatory pro-
cess in response to incipient pathology in regions affected in FTD. To the
best of our knowledge, our ﬁndings are the ﬁrst evidence of a neuropath-
ological substrate of phFTD and to possibly place it in an FTD spectrum.
This may serve as the basis for further assessment in larger patient sam-
ples with longitudinal clinical and pathological follow-up.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nicl.2016.03.019.
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